Clinical and biological implications of CD133-positive and CD133-negative cells in glioblastomas

Kyeung Min Joo, Shi Yean Kim, Xun Jin, Sang Yong Song, Doo Sik Kong, Jung Ii Lee, Ji Won Jeon, Mi Hyun Kim, Bong Gu Kang, Yong Jung, Juyoun Jin, Seung Chyul Hong, Woong Yang Park, Dong Sup Lee, Hyunggee Kim, Do Hyun Nam

Research output: Contribution to journalArticlepeer-review

291 Citations (Scopus)


A number of recent reports have demonstrated that only CD133-positive cancer cells of glioblastoma multiforme (GBM) have tumor-initiating potential. These findings raise an attractive hypothesis that GBMs can be cured by eradicating CD133-positive cancer stem cells (CSCs), which are a small portion of GBM cells. However, as GBMs are known to possess various genetic alterations, GBMs might harbor heterogeneous CSCs with different genetic alterations. Here, we compared the clinical characteristics of two GBM patient groups divided according to CD133-positive cell ratios. The CD133-low GBMs showed more invasive growth and gene expression profiles characteristic of mesenchymal or proliferative subtypes, whereas the CD133-high GBMs showed features of cortical and well-demarcated tumors and gene expressions typical of proneuronal subtype. Both CD133-positive and CD133-negative cells purified from four out of six GBM patients produced typical GBM tumor masses in NOD-SCID brains, whereas brain mass from CD133-negative cells showed more proliferative and angiogenic features compared to that from CD133-positive cells. Our results suggest, in contrast to previous reports that only CD133-positive cells of GBMs can initiate tumor formation in vivo CD133-negative cells also possess tumor-initiating potential, which is indicative of complexity in the identification of cancer cells for therapeutic targeting.

Original languageEnglish
Pages (from-to)808-815
Number of pages8
JournalLaboratory Investigation
Issue number8
Publication statusPublished - 2008 Aug


  • CD133
  • Cancer stem cell
  • Clinical manifestation
  • Gene expression profile
  • Glioblastoma

ASJC Scopus subject areas

  • Pathology and Forensic Medicine
  • Molecular Biology
  • Cell Biology


Dive into the research topics of 'Clinical and biological implications of CD133-positive and CD133-negative cells in glioblastomas'. Together they form a unique fingerprint.

Cite this